Radiation sterilisation of cultured human brain tumour cells for clinical immune tumour therapy

被引:0
|
作者
C Bauréus-Koch
G Nyberg
B Widegren
L G Salford
B R R Persson
机构
[1] Lund University Hospital,Department of Radiation Physics
[2] Klinikgatan 7,Department of Neurosurgery
[3] Tumour Immunology,Department of Radiation Physics
[4] Lund University,undefined
[5] Lund University Hospital,undefined
[6] The Rausing Laboratory,undefined
[7] Lund University,undefined
[8] Lund University Hospital,undefined
来源
British Journal of Cancer | 2004年 / 90卷
关键词
glioblastoma multiforme; Cs-; rays; mean lethal dose; MTT; H-thymidine; interferon-; immunisation;
D O I
暂无
中图分类号
学科分类号
摘要
The aim is to investigate the radiosensitivity of noninfected cultured human glioma cells to ascertain that intracutaneously administered cells are viable enough to produce interferon-γ but not able to proliferate. Cell cultures were established from five patients undergoing brain tumour surgery. By karyotyping, we found four malignant (three glioblastoma multiforme (GBM), one giant cell glioma) and one normal. The cells were irradiated with 137Cs-γ rays at absorbed dose levels of 0, 20, 40, 60, 80, 100 and 120 Gy. The fraction of viable cells was examined by MTT incorporation assay. The average of the data obtained from three GBM cell cultures was fitted to an exponential model. The parameters were: extrapolation number n=0.85±0.10, mean lethal dose D0=12.4±3.2 Gy and an additional uncertainty parameter δS=0.14±0.03. By setting δS=0, the corresponding values of the parameters were n=0.86±0.16 and D0=30.0±8.1 Gy. The rate of proliferation was examined by 3H-thymidine incorporation. The average of the proliferation data obtained from three GBM cell cultures was fitted to an exponential model yielding n=0.943±0.005 and D0=5.8±0.5 Gy for δS=0.057±0.005, and by setting δS=0, n=1.00±0.02 and D0=8.4±1.6 Gy. No outgrowth of plated cells was observed after 4 weeks at an absorbed dose of 100 Gy. This absorbed dose is recommended for irradiation of 2 × 106 glioma cells used for clinical immunisation.
引用
收藏
页码:48 / 54
页数:6
相关论文
共 50 条
  • [21] Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
    Hoelzel, Michael
    Bovier, Anton
    Tueting, Thomas
    NATURE REVIEWS CANCER, 2013, 13 (05) : 365 - U95
  • [22] Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
    Michael Hölzel
    Anton Bovier
    Thomas Tüting
    Nature Reviews Cancer, 2013, 13 : 365 - 376
  • [23] CHARACTERISATION OF HUMAN BRAIN TUMOUR INITIATING CELLS LEADING INVASION
    Leidgens, V. J.
    Alieva, M.
    Lu, X.
    Patwary, N.
    Kerkhoff, E.
    Proescholdt, M. J. M.
    Vollmann-Zwerenz, A.
    van Rheenen, J.
    Klein, C. A.
    Hau, P.
    NEURO-ONCOLOGY, 2017, 19 : 11 - 11
  • [24] Tumour Promoting Macrophages and Immune Cells
    Mantovani, A.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S10 - S10
  • [25] Clinical modulation of tumour immune infiltrates and plasma cytokines by ATR inhibition ± radiation
    Dillon, M.
    McLaughlin, M.
    Patin, E.
    Malin, P.
    Ragulan, C.
    Elisa, F.
    Wilkins, A.
    Melcher, A.
    Harrington, K.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S25 - S26
  • [26] Advances in brain tumour classification and therapy
    Preusser, Matthias
    Marosi, Christine
    NATURE REVIEWS NEUROLOGY, 2017, 13 (02) : 71 - 72
  • [27] Advances in brain tumour classification and therapy
    Matthias Preusser
    Christine Marosi
    Nature Reviews Neurology, 2017, 13 : 71 - 72
  • [28] New avenues for brain tumour therapy
    Charlotte Harrison
    Nature Reviews Drug Discovery, 2011, 10 (11) : 816 - 816
  • [29] An immune edited tumour versus a tumour edited immune system:: prospects for immune therapy of acute myeloid leukaemia
    Chan, L
    Hardwick, NR
    Guinn, BA
    Darling, D
    Gäken, J
    Galea-Lauri, J
    Ho, AY
    Mufti, GJ
    Farzaneh, F
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (08) : 1017 - 1024
  • [30] An immune edited tumour versus a tumour edited immune system: prospects for immune therapy of acute myeloid leukaemia
    Lucas Chan
    Nicola R. Hardwick
    Barbara-ann Guinn
    Dave Darling
    Joop Gäken
    Joanna Galea-Lauri
    Aloysius Y. Ho
    Ghulam J. Mufti
    Farzin Farzaneh
    Cancer Immunology, Immunotherapy, 2006, 55 : 1017 - 1024